The Clostridium difficile infection market is anticipated to surge owing to the launch of emerging therapies. The potential emerging treatment expected to launch in the forecast period includes
DUBLIN, Dec. 6, 2022 /PRNewswire/ Endo International plc (OTC: ENDPQ) announced today that it will cease the production and sale of Endo Aesthetics' Qwo (collagenase clostridium histolyticum-aaes)
A fecal microbial transplant -; giving a recipient fecal matter from a donor to change the recipient's gut microbial community in the colon -; has been a successful last resort therapy for people with recurrent Clostridium difficile infection after multiple rounds of suppressive antibiotics have eliminated the recipient microbial community.